JNJ-64264681

DRUG4 trials

Sponsors

Janssen Research & Development, LLC

Conditions

Chronic Lymphocytic LeukemiaHealthyLeukemia, Lymphocytic, Chronic, B-CellLeukemia, Myeloid, AcuteLymphoma, Non-HodgkinMetastatic Castration-resistant Prostate Cancer (mCRPC)Myelodysplastic SyndromesNeoplasms

Phase 1

A Study to Investigate the Safety, Tolerability, and Pharmacokinetics of JNJ-64264681 in Healthy Male and Female Participants

CompletedNCT03607513

Janssen Research & Development, LLCHealthy

Start: 2018-07-31End: 2019-08-09Updated: 2025-02-03

A Study of JNJ-64264681 in Participants With Non-Hodgkin Lymphoma and Chronic Lymphocytic Leukemia

CompletedNCT04210219

Janssen Research & Development, LLCLeukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, Non-Hodgkin

Start: 2020-07-02End: 2025-05-28Updated: 2025-08-21

A Study of JNJ-64264681 and JNJ-67856633 in Participants With Non-Hodgkin Lymphoma and Chronic Lymphocytic Leukemia

CompletedNCT04657224

Janssen Research & Development, LLCChronic Lymphocytic Leukemia, Lymphoma, Non-Hodgkin

Start: 2021-02-25End: 2025-01-16Updated: 2025-08-21

A Rollover Study for Continued Study Treatment and Ongoing Safety Monitoring

Enrolling by invitationNCT06788509

Janssen Research & Development, LLCLeukemia, Lymphocytic, Chronic, B-Cell, Leukemia, Myeloid, Acute, Lymphoma, Non-Hodgkin +4

Start: 2024-12-30End: 2028-01-21Target: 80Updated: 2025-10-10